Clinic
Christus Health Southwestern Louisiana
Christus Health Southwestern Louisiana was paid $11.89M by Medicaid between Jan 2018 and Dec 2024, across 135 billing codes. Its largest line is 99284, emergency room visit (serious) — 33% of everything it billed.
33Billing provider infoCHRISTUS HEALTH SOUTHWESTERN LOUISIANA
LAKE CHARLES, LA 70605
LAKE CHARLES, LA 70605
33aNPI1548796378assigned 05/11/2017
33bProvider typeAmbulatory Surgical Clinic/Center
28Total paid$11.89M
24GClaims398,752
24DCodes billed135
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Ambulatory Surgical Clinic/Center providers in Louisiana
Rank by total paid#3 of 58
Median peer was paid$142K
This provider vs. median83×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official TREVINO, PAUL controls 11+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 44,315 | $1.33M | |
| 2019 | 59,088 | $1.17M | |
| 2020 | 40,409 | $649K | |
| 2021 | 46,194 | $1.39M | |
| 2022 | 77,212 | $2.42M | |
| 2023 | 76,626 | $2.66M | |
| 2024incomplete | 54,908 | $2.26M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 33% | 31,932 | 27,628 | $3.97M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 29% | 52,729 | 45,527 | $3.40M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.5% | 2,309 | 2,060 | $422K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.5% | 1,053 | 937 | $413K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 3.3% | 10,298 | 9,323 | $388K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.7% | 6,885 | 6,521 | $326K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 2.4% | 51,597 | 12,993 | $283K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | 2.2% | 808 | 700 | $259K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 1.9% | 7,093 | 6,020 | $220K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.4% | 29,434 | 25,344 | $167K |
| 71045 | Radiologic examination, chest; single view | 1.4% | 5,958 | 5,071 | $166K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 1.4% | 6,417 | 5,696 | $163K |
123 more codes
| 80053 | Comprehensive metabolic panel | 1.3% | 19,832 | $157K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.3% | 4,732 | $155K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 1.0% | 13,252 | $123K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 1.0% | 2,391 | $123K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 3,330 | $97K |
| 81025 | <1% | 14,396 | $92K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 296 | $83K |
| 36415 | Collection of venous blood by venipuncture | <1% | 32,596 | $65K |
| 59025 | Fetal non-stress test | <1% | 2,023 | $65K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 1,174 | $58K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,187 | $57K |
| 81001 | <1% | 21,993 | $51K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 370 | $49K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 99 | $45K |
| 87081 | <1% | 10,170 | $40K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,101 | $33K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 5,014 | $31K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,505 | $30K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,929 | $25K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 703 | $21K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 937 | $21K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,248 | $20K |
| 87420 | <1% | 2,060 | $19K | |
| 83690 | <1% | 3,569 | $19K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 808 | $19K |
| 95819 | <1% | 180 | $15K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 293 | $13K |
| 84484 | <1% | 1,424 | $12K | |
| 84145 | <1% | 647 | $12K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 740 | $11K |
| 64721 | <1% | 41 | $10K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 613 | $10K |
| 81003 | <1% | 4,417 | $8K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 330 | $8K |
| 83605 | <1% | 795 | $7K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 83 | $6K |
| G0378 | Hospital observation service, per hour | <1% | 22 | $6K |
| 86140 | <1% | 1,251 | $5K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 192 | $4K |
| 82550 | <1% | 868 | $4K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 12 | $4K |
| 85730 | <1% | 1,018 | $4K | |
| 86160 | <1% | 608 | $4K | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 413 | $4K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 99 | $4K |
| 86038 | <1% | 314 | $3K | |
| 85610 | <1% | 1,073 | $3K | |
| 87040 | <1% | 465 | $3K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 240 | $3K |
| 83735 | <1% | 598 | $3K | |
| 86328 | <1% | 727 | $3K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 15,409 | $2K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 158 | $2K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 16 | $2K |
| 80050 | General health panel | <1% | 63 | $2K |
| 84702 | <1% | 176 | $2K | |
| 74022 | <1% | 40 | $2K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 84 | $2K |
| 82150 | <1% | 389 | $2K | |
| 86480 | <1% | 29 | $2K | |
| 83880 | <1% | 54 | $2K | |
| 85651 | <1% | 471 | $2K | |
| 85379 | <1% | 206 | $2K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 55 | $1K |
| 94760 | <1% | 1,501 | $1K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 30 | $1K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 20 | $1K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 14 | $1K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 22 | $1K |
| 87807 | <1% | 71 | $885.63 | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 33 | $824.05 |
| 86850 | <1% | 520 | $778.68 | |
| 80061 | Lipid panel | <1% | 72 | $737.77 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 719 | $732.22 |
| 87186 | <1% | 95 | $663.15 | |
| 87077 | <1% | 94 | $652.11 | |
| 73620 | <1% | 23 | $638.44 | |
| 73560 | <1% | 23 | $638.44 | |
| 73130 | <1% | 23 | $638.44 | |
| 59430 | <1% | 16 | $597.30 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 240 | $589.17 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 717 | $588.50 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 74 | $534.65 |
| 84439 | <1% | 78 | $524.06 | |
| 84165 | <1% | 53 | $516.84 | |
| 86200 | <1% | 41 | $506.48 | |
| 73521 | <1% | 14 | $460.35 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 126 | $440.59 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 12 | $428.89 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 12 | $428.89 |
| 82553 | <1% | 54 | $349.97 | |
| 84703 | <1% | 71 | $320.00 | |
| 72040 | <1% | 14 | $319.22 | |
| 86901 | <1% | 453 | $318.41 | |
| 86900 | <1% | 453 | $318.41 | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 63 | $316.13 |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | <1% | 341 | $239.04 |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | <1% | 12 | $157.70 |
| 84550 | <1% | 29 | $122.34 | |
| C2617 | Stent, non-coronary, temporary, without delivery system | <1% | 25 | $103.68 |
| 84155 | <1% | 55 | $99.53 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 18 | $98.34 |
| 87340 | <1% | 15 | $93.47 | |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | <1% | 18 | $81.35 |
| 86431 | <1% | 14 | $79.62 | |
| 83615 | <1% | 14 | $78.64 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 975 | $63.28 |
| J2704 | Injection, propofol, 10 mg | <1% | 85 | $45.47 |
| C1769 | Guide wire | <1% | 25 | $44.34 |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 13 | $25.19 |
| 97010 | <1% | 132 | $19.18 | |
| A4351 | Intermittent urinary catheter; straight tip, with or without coating (teflon, silicone, or silicone elastomer, etc.), each | <1% | 352 | $8.82 |
| A4314 | Insertion tray with drainage bag with indwelling catheter, foley type, two-way latex with coating (teflon, silicone, silicone elastomer or hydrophilic, etc.) | <1% | 18 | $8.76 |
| G0499 | Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result | 0% | 15 | $0.00 |
| C1889 | Implantable/insertable device, not otherwise classified | 0% | 505 | $0.00 |
| 99153 | Mod sedat endo service >5yrs | 0% | 97 | $0.00 |
| A9270 | Non-covered item or service | 0% | 16 | $0.00 |
| L8699 | Prosthetic implant, not otherwise specified | 0% | 27 | $0.00 |
| A6223 | Gauze, impregnated with other than water, normal saline, or hydrogel, sterile, pad size more than 16 sq. in., but less than or equal to 48 sq. in., without adhesive border, each dressing | 0% | 45 | $0.00 |
| 99152 | 0% | 168 | $0.00 | |
| 69990 | 0% | 119 | $0.00 | |
| A6402 | Gauze, non-impregnated, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing | 0% | 15 | $0.00 |
| 87339 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialTREVINO, PAUL (CEO)
Parent organizationCHRISTUS HEALTH
| Provider | Location | Paid |
|---|---|---|
| Christus Health Southeast Texas | Beaumont, TX | $21.00M |
| Christus Health Southwestern Louisiana | Lake Charles, LA | $10.18M |
| Christus Health Southeast Texas | Jasper, TX | $5.51M |
| Christus Health Southeast Texas | Jasper, TX | $699K |
| Christus Health Southwestern Louisiana | Lake Charles, LA | $223K |
| Christus Health Southwestern Louisiana | Lake Charles, LA | $145K |
| Christus Health Southwestern Louisiana | Lake Charles, LA | $136K |
| Christus Health Southwestern Louisiana | Grand Chenier, LA | $113K |
| Christus Health Southeast Texas | Kirbyville, TX | $86K |
| Christus Health Southwestern Louisiana | Lake Charles, LA | $41K |
| Christus Health Southeast Texas | Beaumont, TX | $175.14 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.